262 related articles for article (PubMed ID: 30596429)
1. Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation.
Zhou L; Wang Z; Hu C; Zhang C; Kovatcheva-Datchary P; Yu D; Liu S; Ren F; Wang X; Li Y; Hou X; Piao H; Lu X; Zhang Y; Xu G
J Proteome Res; 2019 Mar; 18(3):960-969. PubMed ID: 30596429
[TBL] [Abstract][Full Text] [Related]
2. In silico gene expression analysis reveals glycolysis and acetate anaplerosis in IDH1 wild-type glioma and lactate and glutamate anaplerosis in IDH1-mutated glioma.
Khurshed M; Molenaar RJ; Lenting K; Leenders WP; van Noorden CJF
Oncotarget; 2017 Jul; 8(30):49165-49177. PubMed ID: 28467784
[TBL] [Abstract][Full Text] [Related]
3. Hyperpolarized (13)C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring.
Chaumeil MM; Radoul M; Najac C; Eriksson P; Viswanath P; Blough MD; Chesnelong C; Luchman HA; Cairncross JG; Ronen SM
Neuroimage Clin; 2016; 12():180-9. PubMed ID: 27437179
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Metabolomic Analysis of IDH1
Miyata S; Tominaga K; Sakashita E; Urabe M; Onuki Y; Gomi A; Yamaguchi T; Mieno M; Mizukami H; Kume A; Ozawa K; Watanabe E; Kawai K; Endo H
Sci Rep; 2019 Jul; 9(1):9787. PubMed ID: 31278288
[TBL] [Abstract][Full Text] [Related]
6. Metabolic changes related to the IDH1 mutation in gliomas preserve TCA-cycle activity: An investigation at the protein level.
Dekker LJM; Wu S; Jurriëns C; Mustafa DAN; Grevers F; Burgers PC; Sillevis Smitt PAE; Kros JM; Luider TM
FASEB J; 2020 Mar; 34(3):3646-3657. PubMed ID: 31960518
[TBL] [Abstract][Full Text] [Related]
7. Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylase.
Izquierdo-Garcia JL; Cai LM; Chaumeil MM; Eriksson P; Robinson AE; Pieper RO; Phillips JJ; Ronen SM
PLoS One; 2014; 9(9):e108289. PubMed ID: 25243911
[TBL] [Abstract][Full Text] [Related]
8. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
[TBL] [Abstract][Full Text] [Related]
9. Prognostic role of mitochondrial pyruvate carrier in isocitrate dehydrogenase-mutant glioma.
Karsy M; Guan J; Huang LE
J Neurosurg; 2018 Mar; 130(1):56-66. PubMed ID: 29547090
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics of Glioma.
Feng S; Liu Y
Adv Exp Med Biol; 2021; 1280():261-276. PubMed ID: 33791988
[TBL] [Abstract][Full Text] [Related]
11. Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters.
Viswanath P; Najac C; Izquierdo-Garcia JL; Pankov A; Hong C; Eriksson P; Costello JF; Pieper RO; Ronen SM
Oncotarget; 2016 Jun; 7(23):34942-55. PubMed ID: 27144334
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma.
Yang R; Zhao Y; Gu Y; Yang Y; Gao X; Yuan Y; Xiao L; Zhang J; Sun C; Yang H; Qin J; Li J; Zhang F; Zhang L; Ye J
Oncogene; 2020 Oct; 39(40):6340-6353. PubMed ID: 32855525
[TBL] [Abstract][Full Text] [Related]
13. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI.
Yao J; Chakhoyan A; Nathanson DA; Yong WH; Salamon N; Raymond C; Mareninov S; Lai A; Nghiemphu PL; Prins RM; Pope WB; Everson RG; Liau LM; Cloughesy TF; Ellingson BM
Neuro Oncol; 2019 Sep; 21(9):1184-1196. PubMed ID: 31066901
[TBL] [Abstract][Full Text] [Related]
14. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
[TBL] [Abstract][Full Text] [Related]
15. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
16. Identification of a Prognostic Hypoxia-Associated Gene Set in IDH-Mutant Glioma.
Dao Trong P; Rösch S; Mairbäurl H; Pusch S; Unterberg A; Herold-Mende C; Warta R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257451
[TBL] [Abstract][Full Text] [Related]
17. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
18. Hyperpolarized [1-13C] glutamate: a metabolic imaging biomarker of IDH1 mutational status in glioma.
Chaumeil MM; Larson PE; Woods SM; Cai L; Eriksson P; Robinson AE; Lupo JM; Vigneron DB; Nelson SJ; Pieper RO; Phillips JJ; Ronen SM
Cancer Res; 2014 Aug; 74(16):4247-57. PubMed ID: 24876103
[TBL] [Abstract][Full Text] [Related]
19. A glycolysis-based ten-gene signature correlates with the clinical outcome, molecular subtype and IDH1 mutation in glioblastoma.
Chen C; Shi Y; Li Y; He ZC; Zhou K; Zhang XN; Yang KD; Wu JR; Kung HF; Ping YF; Bian XW
J Genet Genomics; 2017 Nov; 44(11):519-530. PubMed ID: 29169920
[TBL] [Abstract][Full Text] [Related]
20. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.
Turcan S; Makarov V; Taranda J; Wang Y; Fabius AWM; Wu W; Zheng Y; El-Amine N; Haddock S; Nanjangud G; LeKaye HC; Brennan C; Cross J; Huse JT; Kelleher NL; Osten P; Thompson CB; Chan TA
Nat Genet; 2018 Jan; 50(1):62-72. PubMed ID: 29180699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
